Ophthotech Underscores Limitations Of Anti-VEGFs in Wet AMD
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech took aim at ophthalmic rival Regeneron with a panel of physicians who pointed out the short-term nature of and side-effects associated with anti-VEGFs. It also emphasized that doctors want several treatments with distinct mechanisms of action, rather than the co-formulations that Regeneron plans.
You may also be interested in...
MedImmune, Abpro’s Unspecific Plans For Bispecific Antibody Collaboration
The AstraZeneca affiliate and the Boston-area synthetic biology specialist are creating a spinout to develop a bispecific antibody targeting Ang2 and VEGF for undisclosed indications. Cancer and wet age-related macular degeneration seem likely areas of focus.
Biopharma Dealmaking Quarterly Statistics, Q2 2014
Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.
FDA Power v. State Laws: Compounders Want Clarity On Office Use
FDA says traditional compounding pharmacies cannot produce office stock, but some states specifically allow the practice, and the International Academy of Compounding Pharmacists wants help from Congress.